DOCSLIB.ORG

Pharmaceutical Excipients and Drug Metabolism: a Mini-Review

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmaceutical Excipients and Drug Metabolism: a Mini-Review International Journal of Molecular Sciences Review Pharmaceutical Excipients and Drug Metabolism: A Mini-Review Rahul Patel, James Barker and Amr ElShaer * Drug Discovery, Delivery and Patient Care (DDDPC), School of Life Sciences, Pharmacy and Chemistry, Kingston University, Kingston upon Thames, Surrey KT1 2EE, UK; [email protected] (R.P.); [email protected] (J.B.) * Correspondence: [email protected]; Tel.: +44-(0)20-8417-7416 Received: 7 October 2020; Accepted: 20 October 2020; Published: 3 November 2020 Abstract: Conclusions from previously reported articles have revealed that many commonly used pharmaceutical excipients, known to be pharmacologically inert, show effects on drug transporters and/or metabolic enzymes. Thus, the pharmacokinetics (absorption, distribution, metabolism and elimination) of active pharmaceutical ingredients are possibly altered because of their transport and metabolism modulation from the incorporated excipients. The aim of this review is to present studies on the interaction of various commonly-used excipients on pre-systemic metabolism by CYP450 enzymes. Excipients such as surfactants, polymers, fatty acids and solvents are discussed. Based on all the reported outcomes, the most potent inhibitors were found to be surfactants and the least effective were organic solvents. However, there are many factors that can influence the inhibition of CYP450, for instance type of excipient, concentration of excipient, type of CYP450 isoenzyme, incubation condition, etc. Such evidence will be very useful in dosage form design, so that the right formulation can be designed to maximize drug bioavailability, especially for poorly bioavailable drugs. Keywords: Pharmaceutical excipients; metabolism; cytochrome P450 1. Introduction The most popular route for drug delivery is oral administration because of pain avoidance, ease of ingestion, patient compliance and versatility of drug candidates. Moreover, the manufacturing for oral drug delivery systems is less expensive as the production process is simple and there are no requirements for sterile conditions [1]. The growth rate of the oral drug delivery market between 2010 and 2017 was 10.3% [2]. Despite all the benefits of oral delivery, poor bioavailability of oral formulations is a limiting factor that can alter the efficacy and therapeutic effect [3]. Various factors are contributing to low oral bioavailability including physiological factor, high gastric emptying time, the effect of food, intestinal barrier and enzymatic degradation of drugs (Table1). First-pass metabolism is one of the key factors responsible for poor bioavailability. The extensive metabolism of drugs prior to reaching the systemic circulation is known as the first-pass metabolism. After oral administration, the drug is absorbed by the gastrointestinal tract (GIT) and transported to the liver through the portal veins. Then, the drug is metabolized in the liver before reaching systemic circulation, resulting in a low available concentration at the intended target site (Figure1). Due to insu fficient plasma concentrations, the bioavailability of the drug is significantly reduced and therefore a high dose of the drug is required [4]. Int. J. Mol. Sci. 2020, 21, 8224; doi:10.3390/ijms21218224 www.mdpi.com/journal/ijms Int. J. Mol. Sci. 2020, 21, 8224 2 of 21 Table 1. Examples of drugs with very poor bioavailability with reported reasons. Pharmacological Bioavailability Drugs Reasons References Class (%) Poor solubility and Alendronate Bisphosphonates 0.59–0.78 [5–7] absorption Atorvastatin Statins 14 P-gp and CYP450 activities [8–10] Dopamine receptor Bromocriptine 5–10 Extensive first-pass effect [11–13] agonists Poor solubility and Clodronate Bisphosphonates 1 [5–7] absorption Intestinal and hepatic Cytarabine Antimetabolites 20 [14] first-pass D2 receptor Domperidone 15 Gut and liver first-pass [15] antagonists Anthracycline Hepatic and intestinal Doxorubicin 5 [16] antibiotics metabolism Budesonide Corticosteroids 11 Hepatic first-pass effect [17] Poor solubility and Etidronate Bisphosphonates 5 [6,7,13] absorption Calcium channel Felodipine 15 P-gp and CYP450 activities [17] blockers Calcium channel Isradipine 15 P-gp and CYP450 activities [18] blockers Fluvastatin Statins 20 P-gp and CYP450 activities [8–10] Calcium Channel Nimodipine 13 P-gp and CYP450 activities [19] blockers Hyoscine Antispasmodics 20 Hepatic metabolism [20] Dissociative Hepatic and intestinal Ketamine 20 [21] anesthetics metabolism Lovastatin Statins <5 P-gp and CYP450 activities [8–10] Morphine Opioids 20–33 Gut and liver first-pass [22] Acetylcholinesterase Pyridostigmine 14 Poor absorption [23] inhibitors Extensive first-pass but Naloxone Opioid antagonists 2–10 [24] 90% absorption First-pass, enterohepatic Naltrexone Opiate antagonists 5–40 [10] recycling Poor solubility and Pamidronate Bisphosphonates 1 [5–7] absorption Pravastatin Statins 17–34 P-gp and CYP450 activities [8–10] Intestinal and hepatic Prochlorperazine Phenothiazines 20 [25] first-pass Poor solubility and Risedronate Bisphosphonates <1 [5–7] absorption Monoamine Selegiline oxidase type B 20 Extensive first-pass [26] inhibitors Simvastatin Statins 5–48 P-gp and CYP450 activities [8–10] Serotonin receptor Sumatriptan 20 Hepatic first-pass [27] agonists Cholinesterase Tacrine 10–30 Hepatic first-pass [28] inhibitors Adrenergic Extensive first-pass and Terbutaline 9–21 [29] receptor agonists poor absorption Lidocaine Local anesthetics 3 Hepatic first-pass effect [30] Poor solubility and Tiludronate Bisphosphonates 6 [5–7] absorption Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 3 of 21 Intestinal and Prochlorperazine Phenothiazines 20 [25] hepatic first-pass Poor solubility Risedronate Bisphosphonates <1 [5–7] and absorption Monoamine Extensive first- Selegiline oxidase type B 20 [26] pass inhibitors P-gp and Simvastatin Statins 5–48 [8–10] CYP450 activities Serotonin Hepatic first- Sumatriptan 20 [27] receptor agonists pass Cholinesterase Hepatic first- Tacrine 10–30 [28] inhibitors pass Extensive first- Adrenergic Terbutaline 9–21 pass and poor [29] receptor agonists absorption Hepatic first- Lidocaine Local anesthetics 3 [30] pass effect Poor solubility Tiludronate Bisphosphonates 6 [5–7] Int. J. Mol. Sci. 2020, 21, 8224 and absorption 3 of 21 Figure 1. Schematic diagram depicting the route of poor bioavailability after oral administration of Figurethe drugs. 1. Schematic diagram depicting the route of poor bioavailability after oral administration of the drugs. The principle enzymes responsible for first-pass metabolism or biotransformation of drug moleculesThe principle are cytochrome enzymes P450respons (CYP450).ible forCYP450 first-pass includes metabolism a superfamily or biotransformation of hemeproteins of whichdrug is moleculescategorized are cytochrome into families P450 and (CYP450). subfamilies CYP450 based includes on amino a superfamily acid sequence of homologyhemeproteins [31 ].which They is are categorizedallotted a familyinto families number and (for subfamilies instance, CYP1 based or on CYP2) amino followed acid sequence by a subfamily homology letter [31]. (e.g., TheyCYP1A are or allottCYP2Ced a )family and are number distinguished (for instance, by a numberCYP1 or for CYP2) the individualfollowed by enzyme a subfamily or isoforms letter (e.g., (e.g., CYP1ACYP1A2 or or CYP2CCYP2C19) and)[ are31]. distinguished According to by Coller a number et al., thefor the most individual commonly enzyme prescribed or isoforms drugs in (e.g., the UnitedCYP1A2 States or CYP2C19(USA) are) [31]. reported According to be to metabolized Coller et al., by the CYP1, most CYP2 commonly and CYP3 pres families.cribed drugs The most in the common United enzymesStates (USA)responsible are reported for oxidation to be metabolized of approximately by CYP1, 79% CYP2 of and these CYP3 drugs families. are CYP2C9, The most CYP2D6, common CYP2C19 enzymes and CYP3A4/5 [32]. 2. Traditional Strategies to Overcome Pre-Systemic Metabolism Several novel, as well as traditional, methods are being investigated to circumvent drug metabolism. Prodrugs, enzyme inhibitors, polymeric excipients, self-emulsifying drug delivery systems (SEDDS) and liposomes have been investigated over the years as inhibitors to metabolic enzymes. 2.1. Prodrug Approaches Prodrug is one of the common approaches investigated, according to the literature. Approximately 10% of the drugs in the pharmaceutical market are categorized as prodrugs and one third of small molecular weight (Mw) drugs are classified as prodrugs [33–38]. Prodrugs are pharmacologically inert substances which undergo conversion, once inside the body, to release the active ingredient for its therapeutic effect [39,40]. Prodrugs successfully overcome the drug physicochemical and biopharmaceutical obstacles, thus enhancing their pharmacokinetic properties such as oral absorption and metabolism [41,42]. 2.2. Enzyme Inhibitors Another promising strategy to reduce the pre-systemic metabolism is the co-administration of CYP450 inhibitors with orally administered drugs [43]. Probably, the best-known enzyme inhibitor is Int. J. Mol. Sci. 2020, 21, 8224 4 of 21 grapefruit juice, which significantly improves the oral bioavailability of many drugs [44,45]. Food–drug interaction is a common occurrence and can be significant when the drug’s pharmacokinetics are altered. The classic example is the interaction between grapefruit juice and felodipine. Felodipine is known to undergo high pre-systemic metabolism resulting in very low absolute bioavailability
Load more

Recommended publications
  • Ketamine As a Rapid Antidepressant
    BJPsych Advances (2016), vol. 22, 222–233 doi: 10.1192/apt.bp.114.014274 ARTICLE Ketamine as a rapid anti depressant: the debate and implications Roger C. M. Ho & Melvyn W. Zhang Roger Ho is an Associate Professor response rates to SSRIs and NaSSAs are around SUMMARY and consultant psychiatrist in 62% and 67% respectively (Papakostas 2008). the Department of Psychological Ketamine, a synthetic derivative of phencyclidine, Environmental factors such as relationship Medicine, Yong Loo Lin School of is a commonly misused party drug that is Medicine, National University of problems, financial difficulties and comorbid restricted in high-income countries because of Singapore. He has a special interest substance misuse often lead to poor treatment its addictive potential. Ketamine is also used as in psychoneuroimmunology and response, and antidepressants combined with the interface between medicine an anaesthetic in human and veterinary medicine. and psychiatry. Melvyn Zhang In the 1990s, research using ketamine to study the CBT have shown promising results in prevention is a senior resident with the pathophysiology of schizophrenia was terminated of mood disorders (Brenner 2010). Although 70– National Addiction Management owing to ethical concerns. Recently, controversy 90% of patients with depression achieve remission, Service, Institute of Mental Health, surrounding the drug has returned, as researchers around 10–30% are refractory to initial treatment Singapore. Correspondence Dr Roger C. M. have demonstrated that intravenous ketamine but respond to switching or combination of Ho, National University of Singapore, infusion has a rapid antidepressant effect and antidepressants, electroconvulsive therapy (ECT) Department of Psychological have therefore proposed ketamine as a novel or psychotherapy.
    [Show full text]
  • Impaired Hepatic Drug and Steroid Metabolism in Congenital Adrenal
    European Journal of Endocrinology (2010) 163 919–924 ISSN 0804-4643 CLINICAL STUDY Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency Dorota Tomalik-Scharte1, Dominique Maiter2, Julia Kirchheiner3, Hannah E Ivison, Uwe Fuhr1 and Wiebke Arlt School of Clinical and Experimental Medicine, Centre for Endocrinology, Diabetes and Metabolism (CEDAM), University of Birmingham, Birmingham B15 2TT, UK, 1Department of Pharmacology, University Hospital, University of Cologne, 50931 Cologne, Germany, 2Department of Endocrinology, University Hospital Saint Luc, 1200 Brussels, Belgium and 3Department of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, 89019 Ulm, Germany (Correspondence should be addressed to W Arlt; Email: [email protected]) Abstract Objective: Patients with congenital adrenal hyperplasia due to P450 oxidoreductase (POR) deficiency (ORD) present with disordered sex development and glucocorticoid deficiency. This is due to disruption of electron transfer from mutant POR to microsomal cytochrome P450 (CYP) enzymes that play a key role in glucocorticoid and sex steroid synthesis. POR also transfers electrons to all major drug- metabolizing CYP enzymes, including CYP3A4 that inactivates glucocorticoid and oestrogens. However, whether ORD results in impairment of in vivo drug metabolism has never been studied. Design: We studied an adult patient with ORD due to homozygous POR A287P, the most frequent POR mutation in Caucasians, and her clinically unaffected, heterozygous mother. The patient had received standard dose oestrogen replacement from 17 until 37 years of age when it was stopped after she developed breast cancer. Methods: Both subjects underwent in vivo cocktail phenotyping comprising the oral administration of caffeine, tolbutamide, omeprazole, dextromethorphan hydrobromide and midazolam to assess the five major drug-metabolizing CYP enzymes.
    [Show full text]
  • Regulation of Ribulose-1, 5-Bisphosphate Carboxylase
    Plant Physiol. (1993) 102: 21-28 Regulation of Ribulose- 1,5-Bisphosphate Carboxylase/Oxygenase Activity in Response to Reduced Light lntensity in C4 Plants' Rowan F. Sage* and Jeffrey R. Seemann Department of Botany, University of Georgia, Athens, Ceorgia 30602 (R.F.S.); and Department of Biochemistry, University of Nevada, Reno, Nevada 89557 (J.R.S.) tion of Rubisco activity by reversible carbamylation occurs in lhe light-dependent regulation of ribulose-1,5-bisphosphate response to changes in light intensity as well as the concen- carboxylase/oxygenase (Rubisco) activity was studied in 16 species tration of C02and 02,whereas inhibition of Rubisco activity of C, plants representing all three biochemical subtypes and a by CAlP occurs only in response to varying PPFD (Sharkey variety of taxonomic groups. Rubisco regulation was assessed by et al., 1986; Sage et al., 1990; Seemann et al., 1990). At measuring (a) the ratio of initial to total Rubisco activity, which physiological levels of COz in C3 plants (5-10 PM), full reflects primarily the carbamylation state of the enzyme, and (b) carbamylation of Rubisco requires Rubisco activase (Salvucci, total Rubisco activity per mo1 of Rubisco catalytic sites, which 1989; Portis, 1990). In the absence of Rubisco activase, only declines when 2-carboxyarabinitol I-phosphate (CAlP) binds to carbamylated Rubisco. In all species examined, the activity ratio of 20 to 40% of Rubisco catalytic sites are carbamylated under Rubisco declined with a reduction in light intensity, although sub- physiological conditions, leading to a significant inhibition of stantial variation was apparent between species in the degree of photosynthesis (Salvucci, 1989; Portis, 1990).
    [Show full text]
  • Predicting Intestinal and Hepatic First-Pass Metabolism of Orally Administered Testosterone Undecanoate
    applied sciences Article Predicting Intestinal and Hepatic First-Pass Metabolism of Orally Administered Testosterone Undecanoate Atheer Zgair 1,2,* , Yousaf Dawood 1, Suhaib M. Ibrahem 1, Hyun-moon Back 3, Leonid Kagan 3, Pavel Gershkovich 2 and Jong Bong Lee 2 1 College of Pharmacy, University of Anbar, Ramadi 31001, Iraq; [email protected] (Y.D.); [email protected] (S.M.I.) 2 School of Pharmacy, University of Nottingham, Nottingham NG7 2RD, UK; [email protected] (P.G.); [email protected] (J.B.L.) 3 Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA; [email protected] (H.-m.B.); [email protected] (L.K.) * Correspondence: [email protected]; Tel.: +964-(0)-781-777-1463 Received: 2 October 2020; Accepted: 15 October 2020; Published: 18 October 2020 Abstract: The bioavailability of orally administered drugs could be impacted by intestinal and hepatic first-pass metabolism. Testosterone undecanoate (TU), an orally administered ester prodrug of testosterone, is significantly subjected to first-pass metabolism. However, the individual contribution of intestinal and hepatic first-pass metabolism is not well determined. Therefore, the aim of the current study was to predict the metabolic contribution of each site. The hydrolysis–time profiles of TU incubation in human liver microsomes and Caco-2 cell homogenate were used to predict hepatic and intestinal first-pass metabolism, respectively. The in vitro half-life (t1/2 inv) for the hydrolysis of TU in microsomal mixtures was 28.31 3.51 min. By applying the “well-stirred” model, the fraction ± of TU that could escape hepatic first-pass metabolism (F ) was predicted as 0.915 0.009.
    [Show full text]
  • The Self-Inhibitory Nature of Metabolic Networks and Its Alleviation Through Compartmentalization
    ARTICLE Received 30 Oct 2016 | Accepted 23 May 2017 | Published 10 Jul 2017 DOI: 10.1038/ncomms16018 OPEN The self-inhibitory nature of metabolic networks and its alleviation through compartmentalization Mohammad Tauqeer Alam1,2, Viridiana Olin-Sandoval1,3, Anna Stincone1,w, Markus A. Keller1,4, Aleksej Zelezniak1,5,6, Ben F. Luisi1 & Markus Ralser1,5 Metabolites can inhibit the enzymes that generate them. To explore the general nature of metabolic self-inhibition, we surveyed enzymological data accrued from a century of experimentation and generated a genome-scale enzyme-inhibition network. Enzyme inhibition is often driven by essential metabolites, affects the majority of biochemical processes, and is executed by a structured network whose topological organization is reflecting chemical similarities that exist between metabolites. Most inhibitory interactions are competitive, emerge in the close neighbourhood of the inhibited enzymes, and result from structural similarities between substrate and inhibitors. Structural constraints also explain one-third of allosteric inhibitors, a finding rationalized by crystallographic analysis of allosterically inhibited L-lactate dehydrogenase. Our findings suggest that the primary cause of metabolic enzyme inhibition is not the evolution of regulatory metabolite–enzyme interactions, but a finite structural diversity prevalent within the metabolome. In eukaryotes, compartmentalization minimizes inevitable enzyme inhibition and alleviates constraints that self-inhibition places on metabolism. 1 Department of Biochemistry and Cambridge Systems Biology Centre, University of Cambridge, 80 Tennis Court Road, Cambridge CB2 1GA, UK. 2 Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Gibbet Hill Road, Coventry CV4 7AL, UK. 3 Department of Food Science and Technology, Instituto Nacional de Ciencias Me´dicas y Nutricio´n Salvador Zubira´n, Vasco de Quiroga 15, Tlalpan, 14080 Mexico City, Mexico.
    [Show full text]
  • Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid
    Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 231 _____________________________ _____________________________ Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid Cloning, Expression and Catalytic Properties of CYP4F8 and CYP4F21 BY JOHAN BYLUND ACTA UNIVERSITATIS UPSALIENSIS UPPSALA 2000 Dissertation for the Degree of Doctor of Philosophy (Faculty of Pharmacy) in Pharmaceutical Pharmacology presented at Uppsala University in 2000 ABSTRACT Bylund, J. 2000. Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid: Cloning, Expression and Catalytic Properties of CYP4F8 and CYP4F21. Acta Universitatis Upsaliensis. Comprehensive Summaries of Uppsala Dissertations from Faculty of Pharmacy 231 50 pp. Uppsala. ISBN 91-554-4784-8. Cytochrome P450 (P450 or CYP) is an enzyme system involved in the oxygenation of a wide range of endogenous compounds as well as foreign chemicals and drugs. This thesis describes investigations of P450-catalyzed oxygenation of prostaglandins, linoleic and arachidonic acids. The formation of bisallylic hydroxy metabolites of linoleic and arachidonic acids was studied with human recombinant P450s and with human liver microsomes. Several P450 enzymes catalyzed the formation of bisallylic hydroxy metabolites. Inhibition studies and stereochemical analysis of metabolites suggest that the enzyme CYP1A2 may contribute to the biosynthesis of bisallylic hydroxy fatty acid metabolites in adult human liver microsomes. 19R-Hydroxy-PGE and 20-hydroxy-PGE are major components of human and ovine semen, respectively. They are formed in the seminal vesicles, but the mechanism of their biosynthesis is unknown. Reverse transcription-polymerase chain reaction using degenerate primers for mammalian CYP4 family genes, revealed expression of two novel P450 genes in human and ovine seminal vesicles.
    [Show full text]
  • Clinical Pharmacology 1: Phase 1 Studies and Early Drug Development
    Clinical Pharmacology 1: Phase 1 Studies and Early Drug Development Gerlie Gieser, Ph.D. Office of Clinical Pharmacology, Div. IV Objectives • Outline the Phase 1 studies conducted to characterize the Clinical Pharmacology of a drug; describe important design elements of and the information gained from these studies. • List the Clinical Pharmacology characteristics of an Ideal Drug • Describe how the Clinical Pharmacology information from Phase 1 can help design Phase 2/3 trials • Discuss the timing of Clinical Pharmacology studies during drug development, and provide examples of how the information generated could impact the overall clinical development plan and product labeling. Phase 1 of Drug Development CLINICAL DEVELOPMENT RESEARCH PRE POST AND CLINICAL APPROVAL 1 DISCOVERY DEVELOPMENT 2 3 PHASE e e e s s s a a a h h h P P P Clinical Pharmacology Studies Initial IND (first in human) NDA/BLA SUBMISSION Phase 1 – studies designed mainly to investigate the safety/tolerability (if possible, identify MTD), pharmacokinetics and pharmacodynamics of an investigational drug in humans Clinical Pharmacology • Study of the Pharmacokinetics (PK) and Pharmacodynamics (PD) of the drug in humans – PK: what the body does to the drug (Absorption, Distribution, Metabolism, Excretion) – PD: what the drug does to the body • PK and PD profiles of the drug are influenced by physicochemical properties of the drug, product/formulation, administration route, patient’s intrinsic and extrinsic factors (e.g., organ dysfunction, diseases, concomitant medications,
    [Show full text]
  • Somatic Aging Pathways Regulate Reproductive Plasticity in Caenorhabditis Elegans Maria C Ow, Alexandra M Nichitean, Sarah E Hall*
    RESEARCH ARTICLE Somatic aging pathways regulate reproductive plasticity in Caenorhabditis elegans Maria C Ow, Alexandra M Nichitean, Sarah E Hall* Department of Biology, Syracuse University, Syracuse, United States Abstract In animals, early-life stress can result in programmed changes in gene expression that can affect their adult phenotype. In C. elegans nematodes, starvation during the first larval stage promotes entry into a stress-resistant dauer stage until environmental conditions improve. Adults that have experienced dauer (postdauers) retain a memory of early-life starvation that results in gene expression changes and reduced fecundity. Here, we show that the endocrine pathways attributed to the regulation of somatic aging in C. elegans adults lacking a functional germline also regulate the reproductive phenotypes of postdauer adults that experienced early-life starvation. We demonstrate that postdauer adults reallocate fat to benefit progeny at the expense of the parental somatic fat reservoir and exhibit increased longevity compared to controls. Our results also show that the modification of somatic fat stores due to parental starvation memory is inherited in the F1 generation and may be the result of crosstalk between somatic and reproductive tissues mediated by the germline nuclear RNAi pathway. Introduction Evidence indicating that experiences during early development affect behavior and physiology in a stress-specific manner later in life is abundant throughout the animal kingdom (Telang and Wells, *For correspondence: [email protected] 2004; Weaver et al., 2004; Binder et al., 2008; Pellegroms et al., 2009; van Abeelen et al., 2012; Zhao and Zhu, 2014; Canario et al., 2017; Dantzer et al., 2019; Vitikainen et al., 2019).
    [Show full text]
  • Cholesterol Metabolites 25-Hydroxycholesterol and 25-Hydroxycholesterol 3-Sulfate Are Potent Paired Regulators: from Discovery to Clinical Usage
    H OH metabolites OH Review Cholesterol Metabolites 25-Hydroxycholesterol and 25-Hydroxycholesterol 3-Sulfate Are Potent Paired Regulators: From Discovery to Clinical Usage Yaping Wang 1, Xiaobo Li 2 and Shunlin Ren 1,* 1 Department of Internal Medicine, McGuire Veterans Affairs Medical Center, Virginia Commonwealth University, Richmond, VA 23249, USA; [email protected] 2 Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China; [email protected] * Correspondence: [email protected]; Tel.: +1-(804)-675-5000 (ext. 4973) Abstract: Oxysterols have long been believed to be ligands of nuclear receptors such as liver × recep- tor (LXR), and they play an important role in lipid homeostasis and in the immune system, where they are involved in both transcriptional and posttranscriptional mechanisms. However, they are increas- ingly associated with a wide variety of other, sometimes surprising, cell functions. Oxysterols have also been implicated in several diseases such as metabolic syndrome. Oxysterols can be sulfated, and the sulfated oxysterols act in different directions: they decrease lipid biosynthesis, suppress inflammatory responses, and promote cell survival. Our recent reports have shown that oxysterol and oxysterol sulfates are paired epigenetic regulators, agonists, and antagonists of DNA methyl- transferases, indicating that their function of global regulation is through epigenetic modification. In this review, we explore our latest research of 25-hydroxycholesterol and 25-hydroxycholesterol 3-sulfate in a novel regulatory mechanism and evaluate the current evidence for these roles. Citation: Wang, Y.; Li, X.; Ren, S. Keywords: oxysterol sulfates; oxysterol sulfation; epigenetic regulators; 25-hydroxysterol; Cholesterol Metabolites 25-hydroxycholesterol 3-sulfate; 25-hydroxycholesterol 3,25-disulfate 25-Hydroxycholesterol and 25-Hydroxycholesterol 3-Sulfate Are Potent Paired Regulators: From Discovery to Clinical Usage.
    [Show full text]
  • DESCRIPTION CLINICAL PHARMACOLOGY Mechanism Of
    NDA 20-844/ Topamav Sprinkle Capsules Approved Labeling Text Version: 10/26/98 DESCRIPTION Topiramate is a sulfamate-substituted monosaccharide that is intended for use as an antiepileptic drug. TOPAMAX@ (topiramate capsules) Sprinkle Capsules are available as I5 mg, 25 mg and 50mg sprinkle capsules for oral administration as whole capsules or for opening and sprinkling onto soft food. Topiramate is a white crystalline powder with a bitter taste. Topiramate is most soluble in alkaline solutions containing sodium hydroxide or sodium phosphate and hawng a pH of 9 to IO. It is freely soluble in acetone, chloroform, dimethylsulfoxide, and ethanol. The solubility in water is 9.8 mg/mL. Its saturated solution has a pH of 6.3. Topiramate has the molecular formula C,,H,,NO,S and a molecular weight of 339.37. Topiramate is designated chemically as 2,3:4,5-Di-O-isopropylidene-~- D-fructopyranose sulfamate and has the following structural formula: H3C CH3 TOPAMAX” (topiramate capsules) Sprinkle Capsules contain topiramate coated beads in a hard gelatin capsule. The inactive ingredients are: sugar spheres (sucrose and starch), povidone, cellulose acetate, gelatin, silicone dioxide, sodium lauryl sulfate, titanium dioxide, and black pharmaceutical ink. CLINICAL PHARMACOLOGY Mechanism of Action: The precise mechanism by which topiramate exerts its antiseizure effect is unknown; however, electrophysiological and biochemical studies of the effects of topiramate on cultured neurons have revealed three properties that may contribute to topiramate’s antiepileptic efficacy. First, action potentials elicited repetitively by a sustained depolarization of the neurons are blocked by topiramate in a time-dependent manner, suggestive of a state-dependent sodium channel blocking action.
    [Show full text]
  • Plant Protease Inhibitors: a Defense Strategy in Plants
    Biotechnology and Molecular Biology Review Vol. 2 (3), pp. 068-085, August 2007 Available online at http://www.academicjournals.org/BMBR ISSN 1538-2273 © 2007 Academic Journals Standard Review Plant protease inhibitors: a defense strategy in plants Huma Habib and Khalid Majid Fazili* Department of Biotechnology, The University of Kashmir, P/O Naseembagh, Hazratbal, Srinagar -190006, Jammu and Kashmir, India. Accepted 7 July, 2007 Proteases, though essentially indispensable to the maintenance and survival of their host organisms, can be potentially damaging when overexpressed or present in higher concentrations, and their activities need to be correctly regulated. An important means of regulation involves modulation of their activities through interaction with substances, mostly proteins, called protease inhibitors. Some insects and many of the phytopathogenic microorganisms secrete extracellular enzymes and, in particular, enzymes causing proteolytic digestion of proteins, which play important roles in pathogenesis. Plants, however, have also developed mechanisms to fight these pathogenic organisms. One important line of defense that plants have to fight these pathogens is through various inhibitors that act against these proteolytic enzymes. These inhibitors are thus active in endogenous as well as exogenous defense systems. Protease inhibitors active against different mechanistic classes of proteases have been classified into different families on the basis of significant sequence similarities and structural relationships. Specific protease inhibitors are currently being overexpressed in certain transgenic plants to protect them against invaders. The current knowledge about plant protease inhibitors, their structure and their role in plant defense is briefly reviewed. Key words: Proteases, enzymes, protease inhibitors, serpins, cystatins, pathogens, defense. Table of content 1.
    [Show full text]
  • Effect of Statins and ACE Inhibitors Alone and in Combination on Clinical Outcome in Patients with Coronary Heart Disease
    Journal of Human Hypertension (2004) 18, 781–788 & 2004 Nature Publishing Group All rights reserved 0950-9240/04 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease VG Athyros1, DP Mikhailidis3, AA Papageorgiou2, VI Bouloukos1, AN Pehlivanidis1, AN Symeonidis4 and M Elisaf5, for the GREACE Study Collaborative Group 1Atherosclerosis Unit, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece; 2Department of Clinical Biochemistry, Royal Free Hospital, Royal Free and University College Medical School, Pond Street, London, UK; 32nd Propedeutic Department of Internal Medicine, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece; 4Greek Society of General Practitioners, Thessaloniki, Greece; 5Department of Internal Medicine, Medical School, University of Ioannina, Greece We assessed the ‘synergy’ of statins and angiotensin- point in group A was 31%, (95% CI À48 to À6%, P ¼ 0.01) converting enzyme inhibitors (ACEI) in reducing vascu- in comparison to group B, 59% (95% CI À72 to À48%, lar events in patients with coronary heart disease (CHD). Po0.0001) to group C and 63% (95% CI À74 to À51%, The GREek Atorvastatin and CHD Evaluation (GREACE) Po0.0001) to group D. There was no significant Study, suggested that aggressive reduction of low difference in RRR between groups C and D (9%, CI density lipoprotein cholesterol to 2.59 mmol/l À27–10%, P ¼ 0.1). Other factors (eg the blood pressure) (o100 mg/dl) significantly reduces morbidity and mor- that can influence clinical outcome did not differ tality in CHD patients, in comparison to undertreated significantly between the four treatment groups.
    [Show full text]